Subclinical nephrotoxicity in patients with beta-thalassemia: role of urinary kidney injury molecule
- Resource Type
- Authors
- Marwa Zakaria; Hosam E. Salah; Tamer Hassan; Ola Elsayed Nafea; Sherif El Gebaly
- Source
- Drug and chemical toxicology. 45(1)
- Subject
- Adult
medicine.medical_specialty
Iron Overload
Adolescent
Health, Toxicology and Mutagenesis
Urinary system
010501 environmental sciences
Deferoxamine
Toxicology
Iron Chelating Agents
Kidney
01 natural sciences
Gastroenterology
Nephrotoxicity
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
medicine
Humans
Chelation
In patient
Chelation therapy
Child
0105 earth and related environmental sciences
Subclinical infection
Pharmacology
Chemical Health and Safety
business.industry
Deferasirox
beta-Thalassemia
Public Health, Environmental and Occupational Health
Beta thalassemia
General Medicine
medicine.disease
Cross-Sectional Studies
business
030217 neurology & neurosurgery
medicine.drug
- Language
- ISSN
- 1525-6014
We aimed to investigate the role of urinary kidney injury molecule-1 (KIM-1) in detection of subclinical nephrotoxicity in patients with Beta-thalassemia (β-TM) in relation to chelation therapy and to correlate the urinary KIM-1 level with other clinical and laboratory findings. We conducted a cross-sectional study on 66 thalassemic patients. Their ages range from 7 to 22 years. Routine kidney indices and novel urinary KIM/creatinine ratio (U